RESMED INC

ResMed Inc. announced a definitive agreement to sell its MatrixCare business for $490 million in an all-cash transaction, expected to close in the first quarter of fiscal year 2027. This strategic divestment aims to sharpen the company's focus on its core growth areas of sleep, breathing, and connected home-based healthcare. Additionally, ResMed acquired Noctrix Health, LLC in June 2026, expanding its clinical sleep health portfolio with a medical device for restless legs syndrome. The company's product portfolio saw devices contribute 51% and masks/accessories 37% to net revenues in fiscal year 2026.

Resmed announced a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners, a private equity firm focused on healthcare. This divestiture aligns with Resmed's 2030 strategy to concentrate on high-growth, scalable opportunities in sleep health, breathing health, and connected home-based healthcare. The move is expected to strengthen Resmed's ability to reallocate capital and resources towards innovation and long-term value creation. The transaction, which includes MatrixCare and related software offerings, is anticipated to close in the first quarter of Resmed's fiscal year 2027, subject to regulatory approvals.

Resmed announced its plan to release financial and operational results for the fourth quarter of fiscal year 2026 on Thursday, August 6, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results, accessible via the company's investor relations website. A replay of the webcast and a phone replay will be available for a limited period after the live event.

Resmed announced the completion of its acquisition of Noctrix Health, Inc., a medical device company specializing in wearable therapeutics for chronic neurological disorders. This strategic move expands Resmed's clinical sleep health portfolio to include the treatment of Restless Legs Syndrome (RLS), a significant unmet need. Noctrix's Nidra® Tonic Motor Activation (TOMAC) Therapy, an FDA De Novo classified non-invasive treatment, is designed to alleviate RLS symptoms and enhance sleep quality. The acquisition aligns with Resmed's 2030 strategy to scale solutions that improve lives through better sleep and home health technologies.

Resmed announced that Chairman and CEO Mick Farrell and CFO Aaron Bloomer will attend and present at the 46th Annual William Blair Growth Stock Conference on June 2, 2026, in Chicago. The company's webcast presentation is scheduled for approximately 4:40 p.m. Central Time, with live audio-only access and a 90-day replay available on Resmed's investor relations website.

ResMed Inc. announced strong results for Q3 FY2026, with revenue increasing 11% to $1.4 billion and non-GAAP diluted EPS rising 21% to $2.86. The company reported significant gross margin expansion and increased income from operations, driven by demand for sleep devices and masks. Additionally, the board declared a quarterly cash dividend of $0.60 per share, payable on June 18, 2026.

ResMed announced that Brett Sandercock, Chief Financial Officer, plans to retire effective May 4, 2026, after 27 years with the company. Aaron Bloomer, formerly CFO of Exact Sciences, has been appointed as his successor. Sandercock will continue to serve as an advisor to the CEO through the end of calendar year 2027. The company also reiterated its fiscal year 2026 outlook, including gross margin, SG&A, R&D, and effective tax rate.